Atallah-Yunes Suheil Albert, Robertson Michael J
Division of Hematology and Medical Oncology - Melvin and Bren Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN, USA.
Lymphoma Program, Division of Hematology and Medical Oncology - Melvin and Bren Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN, USA.
Leuk Res Rep. 2022 Apr 28;17:100319. doi: 10.1016/j.lrr.2022.100319. eCollection 2022.
The improvement in outcomes seen with the introduction of rituximab, a CD20 monoclonal antibody in combination with chemotherapy or as a single agent in the treatment of indolent non-Hodgkin lymphomas has paved the way for development of various forms of monoclonal antibodies that act in different ways against non-Hodgkin lymphoma tumor cells. These could directly target a single surface antigen resulting in various ways of tumor cells toxicity and killing. Other forms of monoclonal antibodies include antibody-drug conjugates and bispecific antibodies. The role of therapeutic monoclonal antibodies in the treatment of lymphoma will be reviewed, highlighting their mode of action, clinical efficacy, and side effects.
利妥昔单抗（一种CD20单克隆抗体）与化疗联合使用或作为单一药物用于治疗惰性非霍奇金淋巴瘤时，其疗效的改善为开发各种以不同方式作用于非霍奇金淋巴瘤肿瘤细胞的单克隆抗体铺平了道路。这些单克隆抗体可以直接靶向单一表面抗原，从而产生多种导致肿瘤细胞毒性和杀伤的方式。其他形式的单克隆抗体包括抗体-药物偶联物和双特异性抗体。本文将综述治疗性单克隆抗体在淋巴瘤治疗中的作用，重点介绍其作用方式、临床疗效和副作用。
